Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 231

1.

[French ccAFU guidelines - Update 2018-2020: Management of kidney cancer].

Bensalah K, Albiges L, Bernhard JC, Bigot P, Bodin T, Boissier R, Correas JM, Gimel P, Hetet JF, Long JA, Nouhaud FX, Ouzaïd I, Rioux-Leclercq N, Méjean A.

Prog Urol. 2018 Nov;28 Suppl 1:R5-R33. doi: 10.1016/j.purol.2019.01.004. Epub 2019 Aug 23. French.

PMID:
31610874
2.

Serum CD95L Level Correlates with Tumor Immune Infiltration and Is a Positive Prognostic Marker for Advanced High-Grade Serous Ovarian Cancer.

De La Motte Rouge T, Corné J, Cauchois A, Le Boulch M, Poupon C, Henno S, Rioux-Leclercq N, Le Pabic E, Laviolle B, Catros V, Levêque J, Fautrel A, Le Gallo M, Legembre P, Lavoué V.

Mol Cancer Res. 2019 Dec;17(12):2537-2548. doi: 10.1158/1541-7786.MCR-19-0449. Epub 2019 Sep 19.

PMID:
31537619
3.

Diagnosis of uncommon renal epithelial neoplasms: performances of fluorescence in situ hybridization.

Beaumont M, Dugay F, Kammerer-Jacquet SF, Jaillard S, Cabillic F, Mathieu R, Verhoest G, Bensalah K, Rioux-Leclercq N, Belaud-Rotureau MA; CARARE French network (Rare Renal Carcinoma in Adults) of the INCa (National Institute of Cancer, France).

Hum Pathol. 2019 Oct;92:81-90. doi: 10.1016/j.humpath.2019.08.005. Epub 2019 Aug 20.

PMID:
31437522
4.

Colistin-containing cement spacer for treatment of experimental carbapenemase-producing Klebsiella pneumoniae prosthetic joint infection.

Gatin L, Mghir AS, Mouton W, Laurent F, Ghout I, Rioux-Leclercq N, Tattevin P, Verdier MC, Cremieux AC.

Int J Antimicrob Agents. 2019 Oct;54(4):456-462. doi: 10.1016/j.ijantimicag.2019.07.009. Epub 2019 Jul 15.

PMID:
31319190
5.

Controversial issues in Gleason and International Society of Urological Pathology (ISUP) prostate cancer grading: proposed recommendations for international implementation.

Srigley JR, Delahunt B, Samaratunga H, Billis A, Cheng L, Clouston D, Evans A, Furusato B, Kench J, Leite K, MacLennan G, Moch H, Pan CC, Rioux-Leclercq N, Ro J, Shanks J, Shen S, Tsuzuki T, Varma M, Wheeler T, Yaxley J, Egevad L.

Pathology. 2019 Aug;51(5):463-473. doi: 10.1016/j.pathol.2019.05.001. Epub 2019 Jul 3. Review.

PMID:
31279442
6.

Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors.

Verbiest A, Renders I, Caruso S, Couchy G, Job S, Laenen A, Verkarre V, Rioux-Leclercq N, Schöffski P, Vano Y, Elaidi RT, Lerut E, Albersen M, Oudard S, Fridman WH, Sautès-Fridman C, Albigès L, Wozniak A, Zucman-Rossi J, Beuselinck B.

Clin Genitourin Cancer. 2019 Oct;17(5):e981-e994. doi: 10.1016/j.clgc.2019.05.009. Epub 2019 May 25.

PMID:
31229459
7.

Renal Dysfunction in Patients With Direct Infiltration by B-Cell Lymphoma.

Corlu L, Rioux-Leclercq N, Ganard M, Decaux O, Houot R, Vigneau C.

Kidney Int Rep. 2019 Feb 12;4(5):688-697. doi: 10.1016/j.ekir.2019.02.008. eCollection 2019 May.

8.

Percentage grade 4 tumour predicts outcome for clear cell renal cell carcinoma.

Dagher J, Delahunt B, Rioux-Leclercq N, Egevad L, Varma M, Samaratunga H.

Pathology. 2019 Jun;51(4):349-352. doi: 10.1016/j.pathol.2019.01.004. Epub 2019 Apr 12.

PMID:
30987774
9.

Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma.

Kammerer-Jacquet SF, Deleuze A, Saout J, Mathieu R, Laguerre B, Verhoest G, Dugay F, Belaud-Rotureau MA, Bensalah K, Rioux-Leclercq N.

Int J Mol Sci. 2019 Apr 4;20(7). pii: E1692. doi: 10.3390/ijms20071692. Review.

10.

Long-term oncological outcomes of cystic renal cell carcinoma according to the Bosniak classification.

Boissier R, Ouzaid I, Nouhaud FX, Khene Z, Dariane C, Chkir S, Chelly S, Giwerc A, Allenet C, Lefrancq JB, Gimel P, Bodin T, Rioux-Leclercq N, Correas JM, Albiges L, Hetet JF, Bigot P, Bernhard JC, Long JA, Mejean A, Bensalah K; AFU Committee of Urological Oncology.

Int Urol Nephrol. 2019 Jun;51(6):951-958. doi: 10.1007/s11255-019-02085-6. Epub 2019 Apr 12.

PMID:
30977021
11.

Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5.

Giuliano S, Dufies M, Ndiaye PD, Viotti J, Borchiellini D, Parola J, Vial V, Cormerais Y, Ohanna M, Imbert V, Chamorey E, Rioux-Leclercq N, Savina A, Ferrero JM, Mograbi B, Pagès G.

Theranostics. 2019 Jan 30;9(4):1181-1199. doi: 10.7150/thno.29093. eCollection 2019.

12.

Metastatic Clear-cell Renal Cell Carcinoma With a Long-term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 Expression.

Kammerer-Jacquet SF, Brunot A, Lefort M, Bayat S, Peyronnet B, Verhoest G, Mathieu R, Lespagnol A, Mosser J, Laguerre B, Ravaud A, Bernhard JC, Dupuis F, Yacoub M, Belaud-Rotureau MA, Bensalah K, Rioux-Leclercq N.

Clin Genitourin Cancer. 2019 Jun;17(3):169-176.e1. doi: 10.1016/j.clgc.2019.01.014. Epub 2019 Feb 4.

13.

VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness.

Ndiaye PD, Dufies M, Giuliano S, Douguet L, Grépin R, Durivault J, Lenormand P, Glisse N, Mintcheva J, Vouret-Craviari V, Mograbi B, Wurmser M, Ambrosetti D, Rioux-Leclercq N, Maire P, Pagès G.

Theranostics. 2019 Jan 21;9(3):661-675. doi: 10.7150/thno.27794. eCollection 2019.

14.

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.

Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, Grünwald V, Gillessen S, Horwich A; ESMO Guidelines Committee.

Ann Oncol. 2019 May 1;30(5):706-720. doi: 10.1093/annonc/mdz056. No abstract available.

PMID:
30788497
15.

Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study.

Aydin AM, Singla N, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Westerman ME, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V, Krabbe LM.

World J Urol. 2019 Nov;37(11):2419-2427. doi: 10.1007/s00345-019-02678-x. Epub 2019 Feb 13.

PMID:
30759271
16.

Recurrence of Goodpasture syndrome without circulating anti-glomerular basement membrane antibodies after kidney transplant, a case report.

Thibaud V, Rioux-Leclercq N, Vigneau C, Morice S.

BMC Nephrol. 2019 Jan 8;20(1):6. doi: 10.1186/s12882-018-1197-6.

17.

RETRACTED: Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : prise en charge du cancer du reinFrench ccAFU guidelines – Update 2018–2020: Management of kidney cancer

Bensalah K, Albiges L, Bernhard JC, Bigot P, Bodin T, Boissier R, Correas JM, Gimel P, Hetet JF, Long JA, Nouhaud FX, Ouzaïd I, Rioux-Leclercq N, Méjean A.

Prog Urol. 2018 Nov;28(12S):S3-S31. doi: 10.1016/j.purol.2018.09.009. Epub 2018 Oct 26. Review. French. Erratum in: Prog Urol. 2018 Nov;28 Suppl 1:R5-R33.

PMID:
30473002
18.

What Is Better for Predicting Morbidity of Robotic Partial Nephrectomy-A Score or Your Clinical Judgement?

Khene ZE, Peyronnet B, Freton L, Graffeille V, Pradere B, Robert C, Kammerer-Jacquet SF, Verhoest G, Rioux-Leclercq N, Shariat S, Mathieu R, Bensalah K.

Eur Urol Focus. 2018 Nov 12. pii: S2405-4569(18)30317-1. doi: 10.1016/j.euf.2018.10.016. [Epub ahead of print]

PMID:
30442584
19.

Transcriptomic heterogeneity in multifocal prostate cancer.

Salami SS, Hovelson DH, Kaplan JB, Mathieu R, Udager AM, Curci NE, Lee M, Plouffe KR, de la Vega LL, Susani M, Rioux-Leclercq N, Spratt DE, Morgan TM, Davenport MS, Chinnaiyan AM, Cyrta J, Rubin MA, Shariat SF, Tomlins SA, Palapattu GS.

JCI Insight. 2018 Nov 2;3(21). pii: 123468. doi: 10.1172/jci.insight.123468.

20.

Non-Clear Cell Renal Cell Carcinomas: From Shadow to Light.

Albiges L, Flippot R, Rioux-Leclercq N, Choueiri TK.

J Clin Oncol. 2018 Oct 29:JCO2018792531. doi: 10.1200/JCO.2018.79.2531. [Epub ahead of print]

PMID:
30372389
21.

Does mechanical morcellation of large glands compromise incidental prostate cancer detection on specimen analysis? A pathological comparison with open simple prostatectomy.

Misraï V, Kerever S, Pasquie M, Bordier B, Guillotreau J, Palasse J, Guillotreau V, Rijo E, Vincendeau S, Huet R, Mathieu R, Peyronnet B, Rioux-Leclercq N, Compérat EM.

World J Urol. 2019 Jul;37(7):1315-1320. doi: 10.1007/s00345-018-2532-z. Epub 2018 Oct 22.

PMID:
30350017
22.

[Renal amyloidosis revealing a cryopyrin associated periodic syndrome].

Robinet G, Renaudineau E, Lamaison C, Cam G, Rioux-Leclercq N.

Ann Pathol. 2018 Dec;38(6):401-406. doi: 10.1016/j.annpat.2018.07.001. Epub 2018 Sep 17. French.

PMID:
30236822
23.

Assessment of tumour-associated necrosis provides prognostic information additional to World Health Organization/International Society of Urological Pathology grading for clear cell renal cell carcinoma.

Dagher J, Delahunt B, Rioux-Leclercq N, Egevad L, Coughlin G, Dunglison N, Gianduzzo T, Kua B, Malone G, Martin B, Preston J, Pokorny M, Wood S, Samaratunga H.

Histopathology. 2019 Jan;74(2):284-290. doi: 10.1111/his.13737. Epub 2018 Oct 17.

PMID:
30129659
24.

Does tumour effraction during robotic partial nephrectomy have any impact on recurrence?

Khene ZE, Peyronnet B, Pradère B, Robert C, Goujon A, Kammerer-Jacquet SF, Verhoest G, Rioux-Leclercq N, Mathieu R, Bensalah K.

Int J Clin Oncol. 2019 Jan;24(1):87-93. doi: 10.1007/s10147-018-1331-2. Epub 2018 Aug 6.

PMID:
30083964
25.

[Low-grade eosinophilic unclassified renal cell carcinoma, a recently proposed entity in the spectrum of eosinophilic renal cells tumors: Report of one case and discussion].

Thierry S, El Alami-Thomas W, Cazin S, Chiforeanu DC, Medane S, Dugay F, Kammerer-Jacquet SF, Argani P, Laguerre B, Rioux-Leclercq N.

Ann Pathol. 2018 Dec;38(6):395-400. doi: 10.1016/j.annpat.2018.05.013. Epub 2018 Aug 1. Review. French.

PMID:
30077423
26.

Use of 5α-reductase inhibitors for benign prostate hypertrophy and risk of high grade prostate cancer: a French population-based study.

Scailteux LM, Rioux-Leclercq N, Vincendeau S, Balusson F, Nowak E, Oger E; Network of Pathologists in Brittany.

BJU Int. 2019 Feb;123(2):293-299. doi: 10.1111/bju.14495. Epub 2018 Sep 11.

27.

Predicting morbidity after robotic partial nephrectomy: The effect of tumor, environment, and patient-related factors.

Khene ZE, Peyronnet B, Kocher NJ, Robyak H, Robert C, Pradere B, Oger E, Kammerer-Jacquet SF, Verhoest G, Rioux-Leclercq N, Mathieu R, Raman JD, Bensalah K.

Urol Oncol. 2018 Jul;36(7):338.e19-338.e26. doi: 10.1016/j.urolonc.2018.04.005.

PMID:
29759510
28.

Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma.

Singla N, Krabbe LM, Aydin AM, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V.

Urol Oncol. 2018 Jul;36(7):343.e1-343.e8. doi: 10.1016/j.urolonc.2018.04.004. Epub 2018 May 7.

PMID:
29748098
29.

Contemporary assessment of the correlation between Bosniak classification and histological characteristics of surgically removed atypical renal cysts (UroCCR-12 study).

Nouhaud FX, Bernhard JC, Bigot P, Khene ZE, Audenet F, Lang H, Bergerat S, Fraisse G, Grenier N, Cornelis F, Nedelcu C, Béjar S, Fromont-Hankard G, Allory Y, Lindner V, Verkarre V, Daniel L, Yacoub M, Correas JM, Méjean A, Rioux-Leclercq N, Bensalah K.

World J Urol. 2018 Oct;36(10):1643-1649. doi: 10.1007/s00345-018-2307-6. Epub 2018 May 5.

PMID:
29730837
30.

Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma.

Dufies M, Nollet M, Ambrosetti D, Traboulsi W, Viotti J, Borchiellini D, Grépin R, Parola J, Giuliano S, Helley-Russick D, Bensalah K, Ravaud A, Bernhard JC, Schiappa R, Bardin N, Dignat-George F, Rioux-Leclercq N, Oudard S, Négrier S, Ferrero JM, Chamorey E, Blot-Chabaud M, Pagès G.

Theranostics. 2018 Mar 28;8(9):2447-2458. doi: 10.7150/thno.23002. eCollection 2018.

31.

Acute kidney injury during treatment with high-dose cloxacillin: a report of 23 cases and literature review.

Lavergne A, Vigneau C, Polard E, Triquet L, Rioux-Leclercq N, Tattevin P, Golbin L.

Int J Antimicrob Agents. 2018 Sep;52(3):344-349. doi: 10.1016/j.ijantimicag.2018.04.007. Epub 2018 Apr 14. Review.

32.

The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma.

Ambrosetti D, Dufies M, Dadone B, Durand M, Borchiellini D, Amiel J, Pouyssegur J, Rioux-Leclercq N, Pages G, Burel-Vandenbos F, Mazure NM.

PLoS One. 2018 Feb 26;13(2):e0193477. doi: 10.1371/journal.pone.0193477. eCollection 2018.

33.

Fatty acid profile in peri-prostatic adipose tissue and prostate cancer aggressiveness in African-Caribbean and Caucasian patients.

Figiel S, Pinault M, Domingo I, Guimaraes C, Guibon R, Besson P, Tavernier E, Blanchet P, Multigner L, Bruyère F, Haillot O, Mathieu R, Vincendeau S, Rioux-Leclercq N, Lebdai S, Azzouzi AR, Perrouin-Verbe MA, Fournier G, Doucet L, Rigaud J, Renaudin K, Mahéo K, Fromont G.

Eur J Cancer. 2018 Mar;91:107-115. doi: 10.1016/j.ejca.2017.12.017.

PMID:
29413967
34.

Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting.

Verbiest A, Couchy G, Job S, Zucman-Rossi J, Caruana L, Lerut E, Oyen R, de Reyniès A, Laguerre B, Rioux-Leclercq N, Wozniak A, Joniau S, Van Poppel H, Van Den Eynde K, Beuselinck B.

Clin Genitourin Cancer. 2018 Jun;16(3):e605-e612. doi: 10.1016/j.clgc.2017.10.017. Epub 2017 Nov 7.

PMID:
29239846
35.

Metabolic syndrome and low high-density lipoprotein cholesterol are associated with adverse pathological features in patients with prostate cancer treated by radical prostatectomy.

Lebdai S, Mathieu R, Leger J, Haillot O, Vincendeau S, Rioux-Leclercq N, Fournier G, Perrouin-Verbe MA, Doucet L, Azzouzi AR, Rigaud J, Renaudin K, Charles T, Bruyere F, Fromont G.

Urol Oncol. 2018 Feb;36(2):80.e17-80.e24. doi: 10.1016/j.urolonc.2017.09.026. Epub 2017 Nov 16.

PMID:
29153942
36.

Biphasic papillary renal cell carcinoma is a rare morphological variant with frequent multifocality: a study of 28 cases.

Trpkov K, Athanazio D, Magi-Galluzzi C, Yilmaz H, Clouston D, Agaimy A, Williamson SR, Brimo F, Lopez JI, Ulamec M, Rioux-Leclercq N, Kassem M, Gupta N, Hartmann A, Leroy X, Bashir SA, Yilmaz A, Hes O.

Histopathology. 2018 Apr;72(5):777-785. doi: 10.1111/his.13432. Epub 2018 Jan 24.

PMID:
29119638
37.

The pVHL172 isoform is not a tumor suppressor and up-regulates a subset of pro-tumorigenic genes including TGFB1 and MMP13.

Hascoet P, Chesnel F, Jouan F, Le Goff C, Couturier A, Darrigrand E, Mahe F, Rioux-Leclercq N, Le Goff X, Arlot-Bonnemains Y.

Oncotarget. 2017 Jun 6;8(44):75989-76002. doi: 10.18632/oncotarget.18376. eCollection 2017 Sep 29.

38.

Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma.

Beuselinck B, Verbiest A, Couchy G, Job S, de Reynies A, Meiller C, Albersen M, Verkarre V, Lerut E, Méjean A, Patard JJ, Laguerre B, Rioux-Leclercq N, Schöffski P, Oudard S, Zucman-Rossi J.

Acta Oncol. 2018 Apr;57(4):498-508. doi: 10.1080/0284186X.2017.1388927. Epub 2017 Nov 2.

PMID:
29095068
39.

VLITL is a major cross-β-sheet signal for fibrinogen Aα-chain frameshift variants.

Garnier C, Briki F, Nedelec B, Le Pogamp P, Dogan A, Rioux-Leclercq N, Goude R, Beugnet C, Martin L, Delpech M, Bridoux F, Grateau G, Doucet J, Derreumaux P, Valleix S.

Blood. 2017 Dec 21;130(25):2799-2807. doi: 10.1182/blood-2017-07-796185. Epub 2017 Oct 31.

40.

Reliability of urinary cytology and cystoscopy for the screening and diagnosis of bladder cancer in patients with neurogenic bladder: A systematic review.

Alimi Q, Hascoet J, Manunta A, Kammerer-Jacquet SF, Verhoest G, Brochard C, Freton L, Kerdraon J, Senal N, Siproudhis L, Rioux-Leclercq N, Brucker B, Gamé X, Peyronnet B.

Neurourol Urodyn. 2018 Mar;37(3):916-925. doi: 10.1002/nau.23395. Epub 2017 Sep 19.

PMID:
28926124
41.

Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations.

Dugay F, Llamas-Gutierrez F, Gournay M, Medane S, Mazet F, Chiforeanu DC, Becker E, Lamy R, Léna H, Rioux-Leclercq N, Belaud-Rotureau MA, Cabillic F.

Oncotarget. 2017 Jun 8;8(32):53336-53351. doi: 10.18632/oncotarget.18408. eCollection 2017 Aug 8.

42.
43.

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.

Dufies M, Giuliano S, Viotti J, Borchiellini D, Cooley LS, Ambrosetti D, Guyot M, Ndiaye PD, Parola J, Claren A, Schiappa R, Gal J, Frangeul A, Jacquel A, Cassuto O, Grépin R, Auberger P, Bikfalvi A, Milano G, Escudier B, Rioux-Leclercq N, Porta C, Negrier S, Chamorey E, Ferrero JM, Pagès G.

Br J Cancer. 2017 Sep 26;117(7):947-953. doi: 10.1038/bjc.2017.276. Epub 2017 Aug 29.

44.

[Tubulocystic renal cell carcinoma with poorly differentiated foci].

Derquin F, Moreau S, Dargent F, Rioux Leclercq N; les membres du réseau Carare.

Ann Pathol. 2017 Aug;37(4):318-320. doi: 10.1016/j.annpat.2017.05.003. Epub 2017 Jul 18. French.

PMID:
28732560
45.

Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading.

Dagher J, Delahunt B, Rioux-Leclercq N, Egevad L, Srigley JR, Coughlin G, Dunglinson N, Gianduzzo T, Kua B, Malone G, Martin B, Preston J, Pokorny M, Wood S, Yaxley J, Samaratunga H.

Histopathology. 2017 Dec;71(6):918-925. doi: 10.1111/his.13311. Epub 2017 Oct 2.

PMID:
28718911
46.

Frequency and Prognostic Value of PTEN Loss in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy.

Rieken M, Shariat SF, Karam JA, Foerster B, Khani F, Gust K, Abufaraj M, Wood CG, Weizer AZ, Raman JD, Guo CC, Rioux-Leclercq N, Haitel A, Bensalah K, Lotan Y, Bachmann A, De Marzo AM, Robinson BD, Margulis V.

J Urol. 2017 Dec;198(6):1269-1277. doi: 10.1016/j.juro.2017.06.096. Epub 2017 Jul 12.

PMID:
28709887
47.

Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma.

Krabbe LM, Heitplatz B, Preuss S, Hutchinson RC, Woldu SL, Singla N, Boegemann M, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Rapoport LM, Glybochko PV, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Xylinas E, Margulis V.

J Urol. 2017 Dec;198(6):1253-1262. doi: 10.1016/j.juro.2017.06.086. Epub 2017 Jun 28.

PMID:
28668287
48.

Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatment.

Kammerer-Jacquet SF, Brunot A, Bensalah K, Campillo-Gimenez B, Lefort M, Bayat S, Ravaud A, Dupuis F, Yacoub M, Verhoest G, Peyronnet B, Mathieu R, Lespagnol A, Mosser J, Edeline J, Laguerre B, Bernhard JC, Rioux-Leclercq N.

Urol Oncol. 2017 Oct;35(10):603.e7-603.e14. doi: 10.1016/j.urolonc.2017.05.015. Epub 2017 Jun 12.

49.

Warfarin-related nephropathy induced by three different vitamin K antagonists: analysis of 13 biopsy-proven cases.

Golbin L, Vigneau C, Touchard G, Thervet E, Halimi JM, Sawadogo T, Lagoutte N, Siohan P, Zagdoun E, Hertig A, Rioux-Leclercq N, Frouget T.

Clin Kidney J. 2017 Jun;10(3):381-388. doi: 10.1093/ckj/sfw133. Epub 2017 Feb 8.

50.

Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy.

Kammerer-Jacquet SF, Medane S, Bensalah K, Bernhard JC, Yacoub M, Dupuis F, Ravaud A, Verhoest G, Mathieu R, Peyronnet B, Brunot A, Laguerre B, Lespagnol A, Mosser J, Dugay F, Belaud-Rotureau MA, Rioux-Leclercq N.

Target Oncol. 2017 Aug;12(4):487-494. doi: 10.1007/s11523-017-0498-1.

PMID:
28550387

Supplemental Content

Loading ...
Support Center